Human leukocyte antigen genetic risk factors of drug-induced liver toxicology

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 3, 2015, Pages 395-409

  Grove, Jane I ^a   Aithal, Guruprasad P ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Adverse drug reaction; Antigen presentation; Drug induced liver injury; MHC

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANALGESIC AGENT; ANTIINFECTIVE AGENT; DICLOFENAC; FLUCLOXACILLIN; HAPTEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; LAPATINIB; LUMIRACOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PROHAPTEN; PYRAZINAMIDE; RIFAMPICIN; UNCLASSIFIED DRUG; XIMELAGATRAN; HLA ANTIGEN;

ADAPTIVE IMMUNITY; ALLELE; CASE CONTROL STUDY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HLA SYSTEM; HUMAN; HYPERSENSITIVITY; IMMUNE SYSTEM; IN VITRO STUDY; LIVER TOXICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; PATHOGENESIS; PHARMACOGENOMICS; REVIEW; TOXIC HEPATITIS; ANIMAL; DRUG-INDUCED LIVER INJURY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; PHARMACOGENETICS; PROCEDURES; RISK FACTOR;

ALLELES; ANIMALS; DRUG-INDUCED LIVER INJURY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HLA ANTIGENS; HUMANS; PHARMACOGENETICS; RISK FACTORS;

EID: 84923021636     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.992414     Document Type: Review

References (92)

1. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451-5
2. Bjornsson ES, Bergmann OM, Bjornsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013;144:1419-25.1425 e1411-1413; quiz e1419-1420
3. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. BMJ 1998;316:1295-8
4. Björnsson E, Aithal G. Immune-mediated drug-induced liver injury. In: Gershwin ME, Vierling JM, Manns MP, editors. Liver immunology. New York, NY: Springer International Publishing; 2014. p. 401-12
5. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. Philidelphia, PA: Lippincott Williams & Wilkins; 1999
6. Han D, Dara L, Win S, et al. Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria. Trends Pharmacol Sci 2013;34:243-53
7. Adams DH, Ju C, Ramaiah SK, et al. Mechanisms of immune-mediated liver injury. Toxicol Sci 2010;115:307-21
8. Daly AK. Human leukocyte antigen (HLA) pharmacogenomic tests: potential and pitfalls. Curr Drug Metab 2014;15:196-201
9. Larrey D, Berson A, Habersetzer et al. Genetic predisposition to drug hepatotoxicity: role in hepatitis caused by amineptine, a tricyclic antidepressant. Hepatology 1989;10:168-73
10. Yip VL, Alfirevic A, Pirmohamed M. Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review. Clin Rev Allergy Immunol 2014:1-11
11. Karlin E, Phillips E. Genotyping for severe drug hypersensitivity. Curr Allergy Asthma Rep 2014;14:418
12. Chan SH, Tan T. HLA and allopurinol drug eruption. Dermatologica 1989;179:32-3
13. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B∗5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-32
14. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002;359:1121-2
15. Ulrich RG. Idiosyncratic toxicity: a convergence of risk factors. Annu Rev Med 2007;58:17-34
16. Urban TJ, Goldstein DB, Watkins PB. Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? Pharmacogenomics 2012;13:735-8
17. Monshi MM, Faulkner L, Gibson A, et al. Human leukocyte antigen (HLA)-B∗57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013;57:727-39.
18. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045
19. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-5
20. Pradeu T, Cooper EL. The danger theory: 20 years later. Front Immunol 2012;3:287
21. Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology 2012;143:1158-72
22. Rodriguez-Pena R, Lopez S, Mayorga C, et al. Potential involvement of dendritic cells in delayed-type hypersensitivity reactions to beta-lactams. J Allergy Clin Immunol 2006;118:949-56
23. Ibanez L, Perez E, Vidal X, et al. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002;37:592-600
24. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-21
25. Bjornsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 2007;25:1411-21
26. Stephens C, Lopez-Nevot MA, Ruiz-Cabello F, et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One 2013;8:e68111.
27. Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999;117:1181-6
28. O'Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000;47:717-20
29. Donaldson PT, Daly AK, Henderson J, et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010;53:1049-53
30. Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011;141:338-47.
31. Donaldson P. Immunogenetics of autoimmune liver disease. In: Gershwin ME, Vierling J, Manns M, editors. Liver immunology. Totowa, NJ: Humana Press; 2007. p. 221-33
32. Saide K, Kim S, Yuan Y, et al. Identification of susceptible HLA class II co-amoxiclav genotypes based on the analysis of drug-specific T-cells from patients with liver injury. Clin Transl Allergy 2014;4(Suppl 3):O3
33. Russmann S, Kaye JA, Jick SS, Jick H. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol 2005;60:76-82
34. Baldo BA, Pham NH, Weiner J. Detection and side-chain specificity of IgE antibodies to flucloxacillin in allergic subjects. J Mol Recognit 1995;8:171-7
35. Lakehal F, Dansette PM, Becquemont L, et al. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol 2001;14:694-701
36. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B∗5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009;41:816-19.
37. Maria VA, Victorino RM. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 1997;41:534-40
38. Wuillemin N, Terracciano L, Beltraminelli H, et al. T cells infiltrate the liver and kill hepatocytes in HLA-B (∗)57:01-associated floxacillin-induced liver injury. Am J Pathol 2014;184:1677-82
39. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005;28:351-70
40. Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008;8:186-95
41. Kenne K, Skanberg I, Glinghammar B, et al. Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol In Vitro 2008;22:730-46
42. Edling Y, Sivertsson L, Andersson TB, et al. Pro-inflammatory response and adverse drug reactions: mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model. Toxicol In Vitro 2008;22:1588-94
43. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol 2008;21:84-92
44. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011;123:1436-50
45. Singer JB, Lewitzky S, Leroy E, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010;42:711-14
46. Pariente EA, Hamoud A, Goldfain D, et al. [Hepatitis caused by clometacin (Duperan). Retrospective study of 30 cases. A model of autoimmune drug-induced hepatitis?]. Gastroenterol Clin Biol 1989;13:769-74
47. Aithal GP. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol 2011;7:139-50
48. Sharma SK, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166:916-19
49. Spraggs CF, Budde LR, Briley LP, et al. HLA-DQA1∗02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011;29:667-73
50. Schaid DJ, Spraggs CF, McDonnell SK, et al. Prospective validation of HLA-DRB1∗07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. J Clin Oncol 2014;32:2296-303
51. Yuan J, Guo S, Hall D, et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 2011;25:1271-80
52. Phillips E, Bartlett JA, Sanne I, et al. Associations between HLA-DRB1∗0102, HLA-B∗5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr 2013;62:e55-7
53. Sharma AM, Li Y, Novalen M, et al. Bioactivation of nevirapine to a reactive quinone methide: implications for liver injury. Chem Res Toxicol 2012;25:1708-19
54. Keane NM, Pavlos RK, McKinnon E, et al. HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity. AIDS 2014;28:1891-901
55. Hirata K, Takagi H, Yamamoto M, et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 2008;8:29-33
56. Kurosaki M, Takagi H, Mori M. HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin. Dig Dis Sci 2000;45:1103-8
57. Park BK, Laverty H, Srivastava A, et al. Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity. Chem Biol Interact 2011;192:30-6
58. Pichler WJ. Consequences of drug binding to immune receptors: immune stimulation following pharmacological interaction with immune receptors (T-cell receptor for antigen or human leukocyte antigen) with altered peptide-human leukocyte antigen or peptide. Dermatologica Sinica 2013;31:181-90.
59. Megherbi R, Kiorpelidou E, Foster B, et al. Role of protein haptenation in triggering maturation events in the dendritic cell surrogate cell line THP-1. Toxicol Appl Pharmacol 2009;238:120-32
60. Aithal GP, Ramsay L, Daly AK, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004;39:1430-40
61. Carey MA, van Pelt FN. Immunochemical detection of flucloxacillin adduct formation in livers of treated rats. Toxicology 2005;216:41-8
62. Jenkins RE, Meng X, Elliott VL, et al. Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo. Proteomics Clin Appl 2009;3:720-9
63. Callan HE, Jenkins RE, et al. Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation. Chem Res Toxicol 2009;22:937-48
64. Whitaker P, Meng X, Lavergne SN, et al. Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis. J Immunol 2011;187:200-11
65. Wuillemin N, Adam J, Fontana S, et al. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin. J Immunol 2013;190:4956-64.
66. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002;2:301-5
67. Zanni MP, von Greyerz S, Schnyder B, et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 1998;102:1591-8
68. Schnyder B, Mauri-Hellweg D, Zanni M, et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest 1997;100:136-41
69. Yun J, Adam J, Yerly D, Pichler WJ. Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA. Allergy 2012;67:1338-46
70. Wei CY, Chung WH, Huang HW, et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012;129:1562-9.e1565
71. Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA 2012;109:9959-64.
72. Yang CW, Hung SI, Juo CG, et al. HLA-B∗1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2007;120:870-7
73. Cheng CY, Su SC, Chen CH, et al. HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review. J Immunol Res 2014;2014:565320
74. Norcross MA, Luo S, Lu L, et al. Abacavir induces loading of novel self-peptides into HLA-B∗57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 2012;26:F21-9
75. Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012;486:554-8
76. Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2012;13:1285-306
77. Bharadwaj M, Illing P, Theodossis A, et al. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol 2012;52:401-31
78. Chessman D, Kostenko L, Lethborg T, et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008;28:822-32
79. Alfirevic A, Pirmohamed M. Predictive genetic testing for drug-induced liver injury: considerations of clinical utility. Clin Pharmacol Ther 2012;92:376-80
80. Phillips EJ, Mallal SA. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2010;11:973-87
81. Guo Y, Shi L, Hong H, et al. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Sci China Life Sci 2013;56:119-24
82. Mallal S, Phillips E, Carosi G, et al. HLA-B∗5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79.
83. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011;89:806-15
84. Aithal GP, Daly AK. Preempting and preventing drug-induced liver injury. Nat Genet 2010;42:650-1
85. Invernizzi P. Drug-induced liver injury: is it time for genetics to change our clinical practice? J Hepatol 2010;53:993-4
86. Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010;138:2246-59
87. Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30
88. Urban TJ, Daly AK, Aithal GP. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis 2014;34:123-33
89. El Sherrif Y, Potts JR, Howard MR, et al. Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations? Liver Int 2013;33:1266-70
90. Carr DF, Alfirevic A, Pirmohamed M. Pharmacogenomics: current state-of-the-art. Genes (Basel) 2014;5:430-43
91. McCarthy MI, Hirschhorn JN. Genome-wide association studies: past, present and future. Hum Mol Genet 2008;17:R100-1
92. Faulkner L, Martinsson K, Santoyo-Castelazo A, et al. The development of in vitro culture methods to characterize primary T-cell responses to drugs. Toxicol Sci 2012;127:150-8